Dosing & Uses
Dosage Forms & Strengths
Indicated for mydriasis in routine diagnostic procedures and in conditions where short-term pupil dilation is desired
Provides clinically significant mydriasis with partial cycloplegia
Dose: 1-2 gtt in the conjunctival sac
Onset of action occurs within 15 minutes
Maximum effect within 60 minutes
Clinically significant dilation, inhibition of pupillary light response, and partial cycloplegia last 3 hours
Mydriasis will reverse spontaneously with time, typically in 6 to 8 hours
In some cases, complete recovery may take up to 24 hours
Safety and efficacy not established
Frequency Not Defined
Photophobia with or without corneal staining
- Psychotic reactions, behavioral disturbances, and vasomotor or cardiorespiratory collapse have been reported with the use of anticholinergic drugs
- Rare but serious cardiovascular events, including death due to myocardial infarction, ventricular fibrillation and significant hypotensive episodes have occurred shortly following instillation
Hypersensitivity to product components
Known or suspected angle-closure glaucoma, presence of a shallow anterior chamber unless gonioscopic observation of the chamber angle is possible; presence of narrow angle where pupil dilation may precipitate angle-closure glaucoma
Monitor patients with cardiac disorders, diabetes mellitus, hypertension or hyperthyroidism
May cause increased intraocular pressure (use with caution in patients with glaucoma)
Possibility of undiagnosed glaucoma should be considered
The elderly may experience intraocular pressure increase following use; use caution
Pregnancy & Lactation
Pregnancy Category: C
Lactation: Unknown if excreted in breast milk, use caution
A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA:Information not available.
Mechanism of Action
Indirect acting sympathomimetic agent; causes mydriasis by stimulating the release of norepinephrine from adrenergic nerve terminasl; blocks acetylcholine resulting in relaxation of cholinergically innervated iris sphincter muscle
Adrenergic innervation to radial muscle is therefore unopposed and pupil becomes dilated
Onset of action: 15 min
Peak effect: 60 min
Duration: 3 hr
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.
|1||This drug is available at the lowest co-pay. Most commonly, these are generic drugs.|
|2||This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.|
|3||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.|
|4||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|5||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|6||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|NC||NOT COVERED – Drugs that are not covered by the plan.|
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.